Brainsway (NASDAQ:BWAY) Price Target Cut to $15.00 by Analysts at HC Wainwright

Brainsway (NASDAQ:BWAY) had its price target trimmed by HC Wainwright from $30.00 to $15.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms also recently commented on BWAY. Weiss Ratings reissued a “hold (c-)” rating on shares of Brainsway in a research note on Monday, December 29th. Northland Securities set a $15.00 target price on Brainsway in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.00.

Brainsway Price Performance

Brainsway stock opened at $13.74 on Thursday. Brainsway has a 12-month low of $3.92 and a 12-month high of $14.65. The stock has a market capitalization of $538.88 million, a PE ratio of 54.96 and a beta of 1.20. The firm has a 50 day simple moving average of $12.04 and a 200-day simple moving average of $9.48.

Brainsway (NASDAQ:BWAY) last announced its earnings results on Wednesday, March 11th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. The firm had revenue of $14.55 million for the quarter, compared to analysts’ expectations of $14.02 million. Brainsway had a return on equity of 11.34% and a net margin of 14.62%. On average, analysts forecast that Brainsway will post 0.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Brainsway

A number of large investors have recently made changes to their positions in the business. Man Group plc lifted its position in shares of Brainsway by 4.5% in the fourth quarter. Man Group plc now owns 18,027 shares of the company’s stock worth $343,000 after purchasing an additional 782 shares in the last quarter. Trexquant Investment LP purchased a new position in Brainsway during the fourth quarter valued at approximately $245,000. Royal Bank of Canada increased its stake in Brainsway by 1,145.9% in the 4th quarter. Royal Bank of Canada now owns 8,410 shares of the company’s stock valued at $160,000 after buying an additional 7,735 shares during the period. Bullseye Asset Management LLC purchased a new stake in Brainsway in the 4th quarter worth approximately $299,000. Finally, ARK Investment Management LLC purchased a new stake in Brainsway in the 4th quarter worth approximately $2,422,000. Institutional investors and hedge funds own 30.11% of the company’s stock.

Key Brainsway News

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: Q4 beat — Brainsway reported $0.14 EPS and $14.6M revenue, topping consensus and showing healthy margin/ROE metrics; management highlighted operational momentum in the quarter. MarketBeat: Q4 results & transcript
• Positive Sentiment: Q4 revenue growth and operational update — company said Q4 revenue grew ~27% and exceeded prior guidance, which underpinned optimism and drove price strength after the print. TheMarketIsOpen: Q4 momentum
• Neutral Sentiment: Earnings materials available — the full Q4/FY2025 results, earnings call transcript and press materials were published (useful for deeper due diligence). Yahoo Finance: Q4 earnings call transcript
• Neutral Sentiment: Reported short-interest data in March appears inconsistent/zero in public feeds (0 shares / NaN changes) — does not provide a clear short-squeeze signal. (No reliable link available.)
• Negative Sentiment: Weaker FY2026 guidance — management guided revenue to $51.0M–$52.0M versus consensus ~ $65M, which is the primary negative catalyst pressuring the stock despite the quarter beat. Benzinga: Q4 beat, guidance below estimates
• Negative Sentiment: Analyst actions — HC Wainwright cut its price target from $30 to $15 (still a Buy), and Northland trimmed its Q1 EPS estimate modestly (from $0.04 to $0.03), which reduces near-term upside expectations. Benzinga: PT change MarketBeat: Analyst note

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.